ClinicalTrials.gg
CompletedNCT05238519ID-FHUpdated Sep 4, 2026

Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

A Phase 3 interventional study of Motivational interview (MI) in Familial Hypercholesterolemia, Cholesterol, Elevated and Genetic Disease, sponsored by Essentia Health. Completed at 2 sites in United States. Open to participants aged 2 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Essentia Health · Phase 3, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
257
Allocation
Randomized
Ages
2 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Hyperlipoproteinemia Type II with a site in United States — 17 open to participants now, 18 under way, 6 of them phase 3. Hyperlipoproteinemia Type II · United States.

Enrollment
29th of 68
257 · median 163
Started
2022
with 5 others
Phase 3
30 of 76
5 open now
Registered
54th of 76
by date

Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, this one is the 29th largest by enrollment of the 68 interventional ones that give a count, is one of 6 that started in 2022, is one of 30 in phase 3, and was the 54th registered.

Hyperlipoproteinemia Type II

251 studies on the registry are indexed under Hyperlipoproteinemia Type II; 57 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

17 of the 76 studies in Hyperlipoproteinemia Type II with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Hyperlipoproteinemia Type II studies recruiting now, 17 (46%) set no upper age limit and 16 (43%) stop at 75 or younger; 17 take children under 18; 6 take healthy volunteers.

This study: 2 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Hyperlipoproteinemia Type II with a site in United States, or all of them as a file.
02

Study summary

The overall goal of this study is to promote awareness of Familial Hypercholesterolemia (FH). The investigators aim to enroll patients with suspected FH into the study and will randomize them to receive usual care or motivational interview. Primary study outcomes include knowledge of FH, as well as clinical and patient-reported outcomes. This study aims to promote optimal disease management and improve outcomes of FH patients.

Read the detailed description

This is a randomized 2-arm study designed to examine the impact of a personalized remote intervention that includes evidence-based risk communication and behavior change techniques with navigation. Patients who meet the inclusion criteria from both Essentia Health (Site A) and Aspirus St. Luke's Hospital (Site B) will be invited to complete the baseline survey. Participants will be randomized to one of two study arms: usual care (UC) and motivational interview (MI). Participant assignment occurs after completion of the baseline survey. Participants randomized to receive a MI will be contacted via telephone or email to schedule a date and time when they are available to receive a video or phone call from the study coordinator. During the MI, participants will be assessed on their readiness to communicate risk with family members. A letter will be sent to the participants physician for notice of the participation in the study. A follow-up survey will be sent to participants approximately 6 months after completion of the baseline survey, in both arms of the study. The study arms will be compared with regard to awareness and treatment of FH (aim 1), as well as the uptake of cascade screening in first- and second-degree relatives (aim 2).

03

Conditions studied

  • Familial Hypercholesterolemia
  • Cholesterol, Elevated
  • Genetic Disease

Keywords

  • cholesterol
  • motivational interview
  • survey
  • cascade screening
04

Who can participate

Ages eligible
2 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 2-75 years
  • patients with existing clinical diagnosis or suspected FH
  • known genetic mutation of FH
  • patients with an initial (pretreatment) LDL level >190 mg/dL or total cholesterol >300 mg/dL (age >19 years) or LDL-c > 160mg/dL or total cholesterol >260 mg/dL in children age 2-19 years
  • patients currently taking a lipid-lowering medication and have an LDL >124 mg/dL or total cholesterol >195 mg/dL
  • capable of providing
  • Patients should reside in Minnesota, Wisconsin or North Dakota.

Exclusion criteria

Exclusion Criteria:

  • Lack of research authorization
  • unable to provide (including non-English speaking individuals)
  • known medical condition other than FH that is thought to contribute to hyperlipidemia (i.e., untreated hypothyroidism, nephrotic syndrome, cholestasis hypopituitarism)
  • Pregnant women and prisoners will also be excluded.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
257 participants (actual)

Study arms

  • Experimental
    Motivational Interview

    Motivational interview arm will receive a message to schedule a follow up motivational interview via telephone or video after the baseline survey as well as follow up surveys.

    Behavioral: Motivational interview (MI)

  • No intervention
    Usual Care

    Usual care arm will receive baseline and follow up surveys only.

Interventions

  • BehavioralMotivational interview (MI)

    The MI intervention is adapted from the CHEERS study intervention (M Health Fairview) found to be effective in promoting lipid screening in patients at increased risk for FH. Within one month of completion of the baseline survey, a study coordinator, who received training in motivational interview integrity, will conduct a 20-40-minute (depending on participant needs) telephone or virtual (zoom) interview with participants randomized to this arm. Participants will be assessed on their readiness to get their cholesterol checked and discuss with family members the risk of FH.

06

What researchers measure

Primary outcomes

  1. Knowledge of familial hypercholesterolemia

    Self-report of knowledge of personal history of FH will be assessed at baseline and follow up

    Time frame: 12 months post intervention

  2. Cascade screening of 1st degree family members

    Cascade screening will be assessed using self-report of either a) discussion about lipid screening with at least one first-degree relative or b) discussion about genetic testing for FH (in the patient's first-degree relatives) within 6 months of the intervention

    Time frame: 6 months post intervention

Secondary outcomes

  1. Proportion of participants with LDL<100

    Percent change in proportion of participants with LDL\<100 from pre-enrollment LDL-c to follow up.

    Time frame: 12 months post enrollment

  2. Proportion of participants with LDL<70

    Percent change in proportion of participants with LDL\<70 from pre-enrollment LDL-c to follow up.

    Time frame: 12 months post enrollment

  3. Absolute change in LDL from baseline to follow up

    Compared absolute and percent lowering of LDL from pre-enrollment LDL-c to follow up.

    Time frame: 12 months post enrollment

  4. Proportion of patients with self-report of genetic testing

    Self-report of completion of a genetic test for familial hypercholesterolemia within 12 months of enrollment

    Time frame: 12 months post enrollment

07

Study locations

2 sites
  • Aspirus St. Luke's Hospital
    Duluth, Minnesota 55805, United States
  • Essentia Health
    Duluth, Minnesota 55805, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Nov 2024, 32 months.

Of 33 phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 32 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2022
First posted
Feb 14, 2022
StartActual
Feb 15, 2022
Primary completionActual
Nov 6, 2024
CompletionActual
Aug 21, 2025
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05238519
Lead sponsor
Essentia Health
Collaborators
WHITESIDE Institute for Clinical Research, Aspirus St. Luke's Hospital
Responsible party
Sponsor
First posted
Feb 14, 2022
Start date
Feb 15, 2022
Primary completion
Nov 6, 2024
Completion
Aug 21, 2025
Last update
Sep 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion